Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 5/20 | 0.36 |
| ▸ | MMP3 | P08254 | 4/20 | 0.36 |
| ▸ | MMP1 | P03956 | 3/20 | 0.36 |
| ▸ | MMP9 | P14780 | 3/20 | 0.36 |
| ▸ | MMP7 | P09237 | 2/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19499071 | 0.83 | SMN1; SMN2 (0.43) | KMT2AHSD17B2SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL16427649 | 0.83 | SMN1; SMN2 (0.43) | KMT2AHSD17B2SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL19497982 | 0.81 | KMT2A (0.43) | KMT2AHSD17B2SMN1; SMN2MAPK1HSD11B1 | |
| SCHEMBL19499465 | 0.80 | KMT2A (0.42) | KMT2AHSD17B2SMN1; SMN2MAPK1MMP2 | |
| SCHEMBL16430035 | 0.79 | ALDH1A1 (0.44) | KMT2ASMN1; SMN2ALDH1A1NPC1RAB9A | |
| SCHEMBL19965134 | 0.78 | SMN1; SMN2 (0.46) | KMT2AHSD17B2SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL18645260 | 0.78 | SMN1; SMN2 (0.46) | KMT2AHSD17B2SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL16428059 | 0.78 | SMN1; SMN2 (0.46) | KMT2AHSD17B2SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL16428060 | 0.78 | SMN1; SMN2 (0.46) | KMT2AHSD17B2SMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL17102255 | 0.78 | SMN1; SMN2 (0.46) | KMT2AHSD17B2SMN1; SMN2ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005774-B2 | Syk inhibitors | GILEAD SCIENCES, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| EP-3027601-B1 | SYK INHIBITORS | GILEAD SCIENCES INC (US) | 2017-10-25 | — | — | EP | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-20160368918-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2016-12-22 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376441-B2 | Substituted pyrrolidines as SYK inhibitors | GILEAD SCIENCES, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| EP-3027601-A1 | SYK INHIBITORS | Gilead Sciences, Inc. (US) | 2016-06-08 | — | — | EP | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015017610-A1 | SYK INHIBITORS | GILEAD SCIENCES, INC. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
| US-20150038488-A1 | SYK INHIBITORS | Kronos Bio, Inc. | 2015-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038488-A1 | SYK INHIBITORS | SYK, BTK, LYN | KMT2A 850/4885HSD17B2 4630/4885SMN1; SMN2 3200/4885 |
| US-20160368918-A1 | SYK INHIBITORS | SYK, BTK, LYN | KMT2A 930/4885HSD17B2 4642/4885SMN1; SMN2 3271/4885 |
| US-10005774-B2 | Syk inhibitors | SYK, BTK, LYN | KMT2A 930/4885HSD17B2 4642/4885SMN1; SMN2 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.